Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech
Feb 10, 02:00 PM
Share
Subscribe
In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and employees alike.
Highlights of the discussion include:
- The EQ imperative: leading through persuasion and influence, not dictates. “It’s not about the science; it’s about the people.”
- The best CEOs follow a four-core formula
- Early stage’s mindset mix (end-game vs journey)—and the rewards of “failing fast”
- Why Series A’s are the “lifeblood of biotech”